The present invention relates to inhibitors of HIF-1 and HIF-2 and uses thereof. The present invention further relates to the inhibitors for use in treatment of diseases. An isolated polypeptide is provided, that prevents dimerization of HIF-1 with HIF-1 and HIF-2 with HIF-1 and/or inhibits the activity of HIF-1 and HIF-2, wherein the polypeptide comprises the amino acid sequence C-X1-X2-X3-Z-X4 (SEQ ID NO 1) and wherein X1, X2, X3 and X4 are any amino acid and wherein Z is leucine, valine of isoleucine or a non-natural derivative or leucine, valine or isoleucine. The isolated polypeptide prevents dimerization of HIF-1 with HIF-1 and HIF-2 with HIF-1 and inhibits the activity of HIF-1 and HIF-2 by binding to HIF-1 or HIF-1 and/or HIF-2 or HIF-1.

A sensor array comprising at least two sensors, wherein each sensor comprises a protein barrel and a reporter dye; wherein the protein barrel defines a lumen; the reporter dye is bound to the lumen reversibly; and wherein the protein barrel is different in structure in the at least two sensors.

Provided herein are systems and methods for characterizing target/ligand engagement. In particular, luciferase-labeled polypeptide targets are used to detect or quantify target/ligand engagement (e.g., within a cell or cell lysate).

The invention provides a BASEHIT screening method for identifying proteins that are involved in host-microbe interactions which may function as therapeutic targets.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

A processing platform in one embodiment comprises one or more processing devices each including at least one processor coupled to a memory. The processing platform is configured to implement a crosslink identification and validation algorithm for processing multiple levels of mass spectrometry data in order to identify and validate protein-protein interactions within the mass spectrometry data. In conjunction with execution of the crosslink identification and validation algorithm, the processing platform is further configured to obtain mass spectrometry spectra for each of the multiple levels, to apply a header matching filter to identify at least one potential crosslink relating one or more first level spectra and one or more second level spectra utilizing a plurality of third level spectra, and to apply one or more mass validation filters to identify whether or not the potential crosslink is a valid crosslink.

The present invention provides assays and assay systems for use in spatially encoded biological assays. The invention provides an assay system comprising an assay capable of high levels of multiplexing where reagents are provided to a biological sample in defined spatial patterns; instrumentation capable of controlled delivery of reagents according to the spatial patterns; and a decoding scheme providing a readout that is digital in nature.

The present disclosure relates generally to compositions and methods for high capacity detection of biological samples. Multiple optical labels as well as their combinations, which may include different ratios of the optical labels, can be used to allow detection of a large number of target molecules, cells, or tissues.

Methods for quantitatively determining a binding kinetic parameter of a molecular binding interaction, for example wherein the determination involves a complex sample, are provided. Aspects of embodiments of the methods include: producing a magnetic sensor device including a complex sample including a magnetic sensor in contact with an assay mixture including a magnetically labeled molecule to produce a detectable molecular binding interaction; obtaining a real-time signal from the magnetic sensor; and quantitatively determining a binding kinetics parameter of the molecular binding interaction from the real-time signal. Also provided are systems and kits configured for use in the methods.

The present invention relates to novel peptides derived from P antigen family member 5 (PAGE5), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.